Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? - PubMed (original) (raw)
Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?
V Leblond et al. J Clin Oncol. 1998 Jun.
Abstract
Purpose: Organ recipients are at a high risk of posttransplant lymphoproliferative disorders (PTLD) as a result of immunosuppressive therapy. Most B-cell lymphomas are associated with Epstein-Barr virus (EBV) infection. We describe a morphologically and clinically distinct group of PTLD in 11 patients that occurred late after organ transplantation and were not associated with EBV.
Patients and methods: There were seven kidney, three heart, and one liver transplant recipients (group I). The clinical manifestations, pathologic findings, treatment, and outcome were compared with those in 21 patients with EBV-associated PTLD treated in our institution (group II). EBV was detected with at least two techniques: Epstein-Barr-encoded RNA (EBER) in situ hybridization with EBER 1 + 2 probes, Southern blotting, and detection of latent membrane protein 1 (LMP1) expression by immunohistochemistry.
Results: The time between transplantation and the diagnosis of lymphoma ranged from 180 to 10,220 days in group I (mean, 2,234; median, 1,800) and from 60 to 2,100 days in group II (mean, 546; median, 180), and was significantly shorter in group II (P = .02). Among 19 tumors diagnosed within 2 years after the graft, 16 were associated with EBV; among 13 tumors diagnosed after more than 2 years, only five were associated with EBV. All of the B-cell PTLDs in group I were classified as monomorphic, meeting the criteria of B diffuse large-cell lymphoma (B-DLCL) with a component of immunoblasts, and genotyping confirmed their monoclonality. Three tumors were T-cell pleomorphic lymphomas. Tumor sites were mainly bone marrow and lymph nodes. Overall median survival was 1 month in group I and 37 months in group II, with two patients still alive in group I and nine in group II. The survival time was significantly longer in group II (P < .01).
Conclusion: EBV-negative PTLD may be a late serious complication of organ transplantation. Half the tumors observed after kidney transplantation in our center were not associated with EBV and emerged after more than 5 years, which suggests the number of EBV-negative PTLDs in organ recipients might increase with time.
Similar articles
- Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study.
Johnson LR, Nalesnik MA, Swerdlow SH. Johnson LR, et al. Am J Surg Pathol. 2006 Dec;30(12):1604-12. doi: 10.1097/01.pas.0000213317.59176.d2. Am J Surg Pathol. 2006. PMID: 17122518 - EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.
Hart M, Thakral B, Yohe S, Balfour HH Jr, Singh C, Spears M, McKenna RW. Hart M, et al. Am J Surg Pathol. 2014 Nov;38(11):1522-9. doi: 10.1097/PAS.0000000000000282. Am J Surg Pathol. 2014. PMID: 25007145 - In situ hybridization for Epstein-Barr virus NotI repeats in posttransplant lymphoproliferative disorder.
Montone KT, Friedman H, Hodinka RL, Hicks DG, Kant JA, Tomaszewski JE. Montone KT, et al. Mod Pathol. 1992 May;5(3):292-302. Mod Pathol. 1992. PMID: 1323104 - [Diffuse lymphoproliferative disease after renal transplantation and its relation with Epstein-Barr virus. Experience at one center].
Franco A, Jiménez L, Aranda I, Alvarez L, González M, Rocamora N, Olivares J. Franco A, et al. Nefrologia. 2002;22(5):463-9. Nefrologia. 2002. PMID: 12497748 Review. Spanish.
Cited by
- Recent Advances in Adult Post-Transplant Lymphoproliferative Disorder.
Markouli M, Ullah F, Omar N, Apostolopoulou A, Dhillon P, Diamantopoulos P, Dower J, Gurnari C, Ahmed S, Dima D. Markouli M, et al. Cancers (Basel). 2022 Dec 1;14(23):5949. doi: 10.3390/cancers14235949. Cancers (Basel). 2022. PMID: 36497432 Free PMC article. Review. - Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience.
Jain A, Nalesnik M, Reyes J, Pokharna R, Mazariegos G, Green M, Eghtesad B, Marsh W, Cacciarelli T, Fontes P, Abu-Elmagd K, Sindhi R, Demetris J, Fung J. Jain A, et al. Ann Surg. 2002 Oct;236(4):429-36; discussion 436-7. doi: 10.1097/00000658-200210000-00005. Ann Surg. 2002. PMID: 12368671 Free PMC article. - Late-onset fatal Epstein-Barr virus-associated hemophagocytic syndrome following cord blood cell transplantation for adult acute lymphoblastic leukemia.
Kawabata Y, Hirokawa M, Saitoh Y, Kosugi S, Yoshioka T, Fujishima M, Fujishima N, Kameoka Y, Saitoh H, Kume M, Takahashi N, Sawada K. Kawabata Y, et al. Int J Hematol. 2006 Dec;84(5):445-8. doi: 10.1532/IJH97.06101. Int J Hematol. 2006. PMID: 17189228 - Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients.
Cesarman E. Cesarman E. Cancer Lett. 2011 Jun 28;305(2):163-74. doi: 10.1016/j.canlet.2011.03.003. Epub 2011 Apr 13. Cancer Lett. 2011. PMID: 21493001 Free PMC article. Review. - Burkitt's Lymphoma Presenting as Late-Onset Posttransplant Lymphoproliferative Disorder following Kidney and Pancreas Transplantation: Case Report and Review of the Literature.
Naik S, Tayapongsak K, Robbins K, Manavi CK, Pettenati MJ, Grier DD. Naik S, et al. Case Rep Oncol. 2013 Jan;6(1):6-14. doi: 10.1159/000346346. Epub 2013 Jan 8. Case Rep Oncol. 2013. PMID: 23466659 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials